99.39
+2.18(+2.24%)
Currency In USD
| Previous Close | 97.21 |
| Open | 99.94 |
| Day High | 100.72 |
| Day Low | 94.62 |
| 52-Week High | 101.06 |
| 52-Week Low | 4.5 |
| Volume | 117,834 |
| Average Volume | 46,422 |
| Market Cap | 613.23M |
| PE | -25.88 |
| EPS | -3.84 |
| Moving Average 50 Days | 47.8 |
| Moving Average 200 Days | 38.8 |
| Change | 2.18 |
If you invested $1000 in Monopar Therapeutics Inc. (MNPR) since IPO date, it would be worth $750.11 as of October 04, 2025 at a share price of $99.39. Whereas If you bought $1000 worth of Monopar Therapeutics Inc. (MNPR) shares 5 years ago, it would be worth $4,056.73 as of October 04, 2025 at a share price of $99.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Sep 24, 2025 3:08 AM GMT
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet m
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
GlobeNewswire Inc.
Sep 24, 2025 3:07 AM GMT
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today annou
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
GlobeNewswire Inc.
Sep 14, 2025 12:00 PM GMT
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today annou